Clin Mol Hepatol > Epub ahead of print
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Chung-Feng Huang1,2,3, Manar Hijaze Awad4, Meital Gal-Tanamy4 , Ming-Lung Yu1.2.5
1Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan
2Faculty of Internal Medicine and Hepatitis Research Center, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3Ph.D. Program in Translational Medicine, College of Medicine, Kaohsiung Medical University and Academia Sinica, Kaohsiung, Taiwan
4Molecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
5School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan
Correspondence :  Meital Gal-Tanamy ,
Tel: +972522959848, Fax: +972522959848, Email: Meital.Tanamy@biu.ac.il
Ming-Lung Yu ,
Tel: +886-7-3121101 ext.7475, Fax: +886-7-3234553, Email: fish6069@gmail.com
Received: June 24, 2024   Accepted: June 29, 2024
*Chung-Feng Huang and Manar Hijaze Awad contributed equally to this work.
KeyWords: HCV; DAA; SVR

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1777
TOTAL : 2093038
Close layer